FindTrial
Sign In

Evaluation of status after allogeneic hematopoietic stem cell transplantation for hematological malignancies

Clinical observation and study on status assessment after allogeneic hematopoietic stem cell transplantation for malignant hematological diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108555
Enrollment
Unknown
Registered
2025-09-01
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, myelodysplastic syndrome, lymphoma, etc.

Interventions

experimental group:None

Sponsors

Henan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with malignant hematological diseases; 2. Patients undergoing allogeneic hematopoietic stem cell transplantation; 3. Those who can be followed up as scheduled according to the experimental plan;

Exclusion criteria

Exclusion criteria: 1. Patients with concomitant malignant tumors; 2. Assessment frequency = 2 times; 3. Those who cannot be followed up as scheduled;

Design outcomes

Primary

MeasureTime frame
Chimerism;minimal residual disease;HLA-loss;—

Countries

China

Contacts

Public ContactXiaodong Lv

Henan Cancer Hospital

13523417973@163.com+86 371 65587244

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026